Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Immutep Ltd    IMM   AU000000IMM6

IMMUTEP LTD

(IMM)
  Report  
End-of-day quote. End-of-day quote AUSTRALIAN SECURITIES EXCHANGE LIMITED - 06/19
0.026 AUD   --.--%
06/13Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial
GL
06/06INSIGHT : First Patient Dosed in the 4th arm called “INSIGHT-004”
GL
06/03Immutep Presentation at ASCO 2019
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Securities Exc…
06/13/2019 06/14/2019 06/17/2019 06/18/2019 06/19/2019 Date
0.026(c) 0.027(c) 0.026(c) 0.026(c) 0.026 Last
1 411 439 2 787 794 1 861 805 2 863 776 2 174 912 Volume
0.00% +3.85% -3.70% 0.00% 0.00% Change
More quotes
Financials (AUD)
Sales 2019 9,48 M
EBIT 2019 -10,3 M
Net income 2019 -9,94 M
Finance 2019 46,7 M
Yield 2019 -
Sales 2020 25,5 M
EBIT 2020 5,85 M
Net income 2020 6,10 M
Finance 2020 50,4 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020 10,40
EV / Sales2019 4,37x
EV / Sales2020 1,48x
Capitalization 88,1 M
More Financials
Company
Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment.... 
More about the company
Surperformance© ratings of Immutep Ltd
Trading Rating : Investor Rating :
More Ratings
Latest news on IMMUTEP LTD
06/13Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients fo..
GL
06/06INSIGHT : First Patient Dosed in the 4th arm called “INSIGHT-004”
GL
06/03Immutep Presentation at ASCO 2019
GL
05/23IMMUTEP : Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunot..
AQ
05/20IMMUTEP : Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unrese..
AQ
05/17IMMUTEP : Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unrese..
AQ
05/10IMMUTEP : Announces Upcoming Industry Conference Participation
AQ
03/27IMMUTEP : to Host Eftilagimod Alpha Clinical Development Update Global Webcast
AQ
03/22IMMUTEP : Announces United States Patent Grant for Eftilagimod Alpha in Cancer
AQ
03/21IMMUTEP : Announces United States Patent Grant for Eftilagimod Alpha in Cancer
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
06/18WHAT'S NEWS : Business & Finance -- WSJ
DJ
06/18PFIZER : Expands Cancer-Treatment Lineup
DJ
06/17ARRAY BIOPHARMA : Pfizer makes $10.6 billion cancer bet in cash deal for Array B..
RE
06/17PFIZER : to Buy Array BioPharma in $10.64 Billion Deal -- 4th Update
DJ
06/17Voyager Therapeutics Up 9%; Restructures Relationship with Sanofi Genzyme
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart IMMUTEP LTD
Duration : Period :
Immutep Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 0,08  AUD
Spread / Average Target 200%
EPS Revisions
Managers
NameTitle
Marc Voigt Chief Executive Officer, CFO & Executive Director
Russell John Howard Non-Executive Chairman
Deanne Miller COO, Secretary & General Counsel
Frédéric Triebel Chief Scientific Officer & Chief Medical Officer
Peter A. Meyers Deputy Chairman
Sector and Competitors
1st jan.Capitalization (M$)
IMMUTEP LTD-7.14%64
IQVIA HOLDINGS INC21.76%26 223
LONZA GROUP31.53%24 012
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION28.70%17 061
EXACT SCIENCES CORPORATION77.35%13 037